Catalent’s (CTLT) Buy Rating Reaffirmed at J P Morgan Chase & Co
J P Morgan Chase & Co reaffirmed their buy rating on shares of Catalent Inc (NASDAQ:CTLT) in a research report sent to investors on Tuesday morning. J P Morgan Chase & Co currently has a $40.00 target price on the stock.
Several other equities analysts have also recently issued reports on CTLT. BidaskClub raised Catalent from a sell rating to a hold rating in a research report on Wednesday, August 16th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $45.00 price objective on shares of Catalent in a research report on Tuesday. Zacks Investment Research raised Catalent from a hold rating to a buy rating and set a $39.00 price objective on the stock in a research report on Tuesday, August 22nd. William Blair raised Catalent from a market perform rating to an outperform rating in a research report on Friday, May 5th. Finally, Bank of America Corporation reiterated a buy rating and set a $37.00 target price (up from $32.00) on shares of Catalent in a research note on Wednesday, May 17th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $35.88.
Catalent (CTLT) opened at 40.27 on Tuesday. The firm’s 50-day moving average price is $35.14 and its 200-day moving average price is $32.37. The company has a market cap of $5.03 billion and a PE ratio of 47.43. Catalent has a one year low of $21.83 and a one year high of $41.37.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The firm had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $547.48 million. During the same period in the previous year, the firm posted $0.52 EPS. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, equities research analysts forecast that Catalent will post $1.60 earnings per share for the current fiscal year.
WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/catalents-ctlt-buy-rating-reaffirmed-at-j-p-morgan-chase-co/1531348.html.
In other Catalent news, SVP Christine Dolan sold 745 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC increased its position in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. Quantbot Technologies LP increased its position in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares during the last quarter. Flinton Capital Management LLC increased its position in shares of Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares during the last quarter. Meadow Creek Investment Management LLC increased its position in shares of Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after buying an additional 559 shares during the last quarter.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.